Novo Nordisk A/S plans to invest €2.1 billion ($2.3 billion) to expand production in France as it works to meet surging demand for its sought-after weight-loss medicines.

The construction work to beef up the Danish company’s site in Chartres, southwest of Paris, has already started, Novo said in a statement. The investment will increase capacity for the diet drug Wegovy and its sister product for diabetes, called Ozempic.